Increased risk of myopathy w/ cyclosporine, fibric acid derivatives, lipid-modifying doses of niacin, CYP3A4 inhibitors (eg, erythromycin & azole antifungals), colchicine. Increased plasma conc w/ CYP3A4 inhibitors (eg, erythromycin, diltiazem, grapefruit juice). Increased bioavailability or AUC w/ OATP1B1 inhibitors (eg, cyclosporine), clarithromycin, protease inhibitors (eg ritonavir, saquinavir, lopinavir), itraconazole. Reduced plasma conc w/ CYP3A4 inducers (eg, efavirenz, rifampin), oral antacid suspension containing Mg & Al hydroxides, colestipol. Increased conc of digoxin. Increased AUC values of OCs containing norethindrone & ethinyl estradiol. Severe muscle problems eg, rhabdomyolysis w/ fusidic acid.